Kirr Marbach & Co. LLC IN decreased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 6.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,919 shares of the medical instruments supplier's stock after selling 1,616 shares during the quarter. Kirr Marbach & Co. LLC IN owned 0.09% of ICU Medical worth $3,401,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC increased its stake in ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock worth $10,790,000 after purchasing an additional 8,010 shares during the period. LMR Partners LLP purchased a new position in ICU Medical in the 3rd quarter worth about $3,884,000. Principal Financial Group Inc. increased its stake in ICU Medical by 24.6% in the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier's stock worth $23,130,000 after buying an additional 25,031 shares during the period. MetLife Investment Management LLC lifted its holdings in ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier's stock valued at $2,258,000 after buying an additional 6,981 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in ICU Medical by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier's stock valued at $99,687,000 after buying an additional 48,106 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at ICU Medical
In related news, Director David C. Greenberg sold 972 shares of the business's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the transaction, the director now directly owns 5,037 shares in the company, valued at $796,400.07. The trade was a 16.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Christian B. Voigtlander sold 1,962 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $169.08, for a total value of $331,734.96. The disclosure for this sale can be found here. Insiders have sold 17,737 shares of company stock worth $2,879,752 over the last quarter. Insiders own 6.70% of the company's stock.
ICU Medical Stock Down 0.9 %
NASDAQ ICUI traded down $1.55 during midday trading on Friday, hitting $164.36. 403,880 shares of the company traded hands, compared to its average volume of 168,844. ICU Medical, Inc. has a 52 week low of $86.80 and a 52 week high of $196.26. The company's 50-day simple moving average is $160.98 and its 200-day simple moving average is $162.28. The company has a market cap of $4.02 billion, a PE ratio of -35.96 and a beta of 0.63. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. KeyCorp raised their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. Finally, StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $199.67.
Read Our Latest Research Report on ICU Medical
ICU Medical Profile
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Further Reading
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
